The clinician's role in promoting resiliency for individuals and families with growth anomalies
dc.contributor.author | Silverman, Howard D | |
dc.contributor.author | Grunauer, Michelle | |
dc.date.accessioned | 2020-05-18T22:35:27Z | |
dc.date.available | 2020-05-18T22:35:27Z | |
dc.date.issued | 2020-01-28 | |
dc.identifier.citation | Silverman, H. D., & Grunauer, M. (2020). The clinician's role in promoting resiliency for individuals and families with growth anomalies. Growth Hormone & IGF Research, 51, 34-37. | en_US |
dc.identifier.issn | 1096-6374 | |
dc.identifier.pmid | 32018120 | |
dc.identifier.doi | 10.1016/j.ghir.2020.01.004 | |
dc.identifier.uri | http://hdl.handle.net/10150/641335 | |
dc.description.abstract | Some recent clinic and population-based studies suggest that severe short stature is not associated with significant behavioral and psychological problems, however collectively studies on this topic are variable and frequently contradictory. In light of these contradictory sources, it is important to recognize that there may be some children for whom growth failure is disabling. Many of such children can respond to counseling and support, but there may be occasions in which therapy can be recommended. Resiliency can be defined as a pattern of positive adaptation in the context of past or present adversity with resiliency in childhood defined as typical development in the face of adverse circumstances that propel others to deleterious outcomes. Several strategies for promoting resilience in short stature patients and their families include 1) conducting a comprehensive psychosocial assessment; 2) recommending psychological strategies to directly address predictable social challenges associated with short stature; 3) discouraging the expectation that taller stature is associated with improvement in quality of life and; 4) discussing treatment efficacy in terms of the degree of certainty and magnitude of effects. Recognizing time constraints in clinical settings, these approaches can be carried out across multiple visits. Being aware of, honoring, and addressing factors the parent and patient use in making their treatment decisions has the potential to promote resiliency in patients and families. This approach to clinical care can serve to promote resiliency in clinicians as well. | en_US |
dc.language.iso | en | en_US |
dc.publisher | ELSEVIER | en_US |
dc.rights | Copyright © 2020 Elsevier Ltd. All rights reserved. | en_US |
dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | en_US |
dc.title | The clinician's role in promoting resiliency for individuals and families with growth anomalies | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1532-2238 | |
dc.contributor.department | Univ Arizona, Coll Med Phoenix | en_US |
dc.identifier.journal | GROWTH HORMONE & IGF RESEARCH | en_US |
dc.description.note | 12 month embargo; available online 28 January 2020 | en_US |
dc.description.collectioninformation | This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. | en_US |
dc.eprint.version | Final accepted manuscript | en_US |
dc.source.journaltitle | Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society | |
dc.source.volume | 51 | |
dc.source.beginpage | 34 | |
dc.source.endpage | 37 | |
dc.source.country | Scotland |